Experimental Hematology & Oncology

Papers
(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Complex roles of cAMP–PKA–CREB signaling in cancer212
CD44 as a tumor biomarker and therapeutic target182
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017122
Risk factors and outcome of COVID-19 in patients with hematological malignancies110
Research progress on dendritic cell vaccines in cancer immunotherapy65
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients65
Engineering better chimeric antigen receptor T cells64
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC63
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–201763
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition56
Role of m6A writers, erasers and readers in cancer55
Macrophage, the potential key mediator in CAR-T related CRS54
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies54
MiRNA-mediated EMT and CSCs in cancer chemoresistance48
Heterogeneity of the tumor immune microenvironment and its clinical relevance46
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma45
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment44
Recent advances and challenges of bispecific antibodies in solid tumors43
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL43
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder42
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes41
COVID-19 vaccination associated severe immune thrombocytopenia37
Breast cancer heterogeneity and its implication in personalized precision therapy36
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia35
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients35
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development35
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma35
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy33
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma32
Current insight into the regulation of PD-L1 in cancer32
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A431
m6A binding protein YTHDF2 in cancer30
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma29
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors29
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy28
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors28
Roles of the intestinal microbiota and microbial metabolites in acute GVHD28
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment27
TCR engineered T cells for solid tumor immunotherapy27
Recent advances in Lynch syndrome27
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 201726
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas24
TRIM family contribute to tumorigenesis, cancer development, and drug resistance24
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China22
Increasing cure rates of solid tumors by immune checkpoint inhibitors22
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si22
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome22
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma21
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas21
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma21
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia21
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review20
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation20
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy20
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes19
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis19
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside19
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin19
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer19
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance19
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis18
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers18
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis18
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio17
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion16
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma16
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy16
p53 amyloid aggregation in cancer: function, mechanism, and therapy16
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy16
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation16
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential16
The metabolic adaptation mechanism of metastatic organotropism16
Function and clinical significance of N6-methyladenosine in digestive system tumours16
Recent updates for antibody therapy for acute lymphoblastic leukemia15
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases15
Targeting metabolic reprogramming in chronic lymphocytic leukemia14
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma14
RHO GTPase family in hepatocellular carcinoma14
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression14
Frontiers in the COVID-19 vaccines development14
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation14
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner14
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment13
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information13
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia13
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing13
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort13
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel13
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway13
Targeting phosphoglycerate dehydrogenase in multiple myeloma13
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma13
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models13
0.072195053100586